KOMO Biosciences, Inc., a next-generation precision genome engineering technology company, today announced the appointment of ...

Precision BioSciences, Inc. (NASDAQ: DTIL), a biotechnology company currently valued at $56 million, held its annual shareholder meeting on May 28, 2025, as detailed in a recent SEC filing.The meeting ...

Check out our DTIL stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Precision BioSciences (DTIL) came out with a quarterly loss of $3.20 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $3.35 per share a year ago.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

- Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision’s in vivo gene editing ...

There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...

Dr. Moraitis brings deep experience in endocrinology to his role leading clinical development for MBX’s lead product ...

Investing.com – U.S. stocks were lower after the close on Monday, as losses in the Healthcare, Utilities and Telecoms sectors led ...